Trade

Watchlist

Portfolio

Message

Set Alert

BSE LIVE NSE LIVE 26 Aug, 2025 12:21 Volume Todays L/H More ×

AstraZeneca Pharma India on Monday said it has partnered with India's largest drugmaker Sun Pharmaceutical Industries to co-market Sodium Zirconium Cyclosilicate (SZC), a therapy for hyperkalaemia, in a bid to widen access to treatment for patients with chronic kidney disease and heart failure.

Under the agreement, AstraZeneca will sell SZC under the brand Lokelma, while Sun Pharma will distribute it as Gimliand. AstraZeneca retains intellectual property rights and marketing authorisation for the molecule.

“This partnership reaffirms our purpose to deliver innovative, life-changing medicines to patients with hyperkalaemia across India,” said Praveen Rao A

See Full Page